The successor trial, AMPLIFY-NEOVAC, specifically aims at demonstrating safety of enhanced peripheral IDH1-vac-induced T cell responses by combined therapy with AVE and investigating intra-glioma abundance and phenotypes of IDH1-vac- and AVE-induced T cells in exploratory post-treatment tissue analyses. This evidence concerns the gene IDH1 and central nervous system cancer.